Progesterone receptor (PR) expression is used as a biomarker of oestrogen receptor-a (ERa) function and breast cancer prognosis. Here we show that PR is not merely an ERa-induced gene target, but is also an ERa-associated protein that modulates its behaviour. In the presence of agonist ligands, PR associates with ERa to direct ERa chromatin binding events within breast cancer cells, resulting in a unique gene expression programme that is associated with good clinical outcome. Progesterone inhibited oestrogen-mediated growth of ERa 1 cell line xenografts and primary ERa 1 breast tumour explants, and had increased anti-proliferative effects when coupled with an ERa antagonist. Copy number loss of PGR, the gene coding for PR, is a common feature in ERa 1 breast cancers, explaining lower PR levels in a subset of cases. Our findings indicate that PR functions as a molecular rheostat to control ERa chromatin binding and transcriptional activity, which has important implications for prognosis and therapeutic interventions.
There is compelling evidence that inclusion of a progestogen as part of hormone replacement therapy increases the risk of breast cancer, implying that PR signalling can contribute towards tumour formation 1 . However, the increased risk of breast cancer associated with progestogen-containing hormone replacement therapy is mainly attributed to specific synthetic progestins, in particular medroxyprogesterone acetate (MPA), which is known to also have androgenic properties 2 . The relative risk is not significant when native progesterone is used 3 . In ERa 1 breast cancers, PR is often used as a positive prognostic marker of disease outcome 4 , but the functional role of PR signalling remains unclear. While activation of PR may promote breast cancer in some women and in some model systems, progesterone treatment has been shown to be antiproliferative in ERa 1 PR 1 breast cancer cell lines [5] [6] [7] , and progestogens have been shown to oppose oestrogen-stimulated growth of an ERa 1 PR 1 patient-derived xenograft 8 . In addition, exogenous expression of PR in ERa 1 breast cancer cells blocks oestrogen-mediated proliferation and ERa transcriptional activity 9 . Furthermore, in ERa 1 breast cancer patients, PR is an independent predictor of response to adjuvant tamoxifen 10 , high levels of PR correlate with decreased metastatic events in early stage disease 11 , and administration of a progesterone injection before surgery can provide improved clinical benefit 12 . These observations imply that PR activation in the context of oestrogen-driven, ERa 1 breast cancer, can have an anti-tumorigenic effect. In support of this, PR agonists can exert clinical benefit in ERa 1 breast cancer patients that have relapsed on ERa antagonists 13 . Breast cancers are typically assessed for ERa, PR and HER2 expression to define histological subtype and guide treatment options. PR is an ERa-induced gene 14 and ERa 1 PR 1 HER2 2 tumours tend to have the best clinical outcome because PR positivity is thought to reflect a tumour that is driven by an active ERa complex and therefore likely to respond to endocrine agents such as tamoxifen or aromatase inhibitors 10, 15 . While ERa 1 PR 1 tumours have a better clinical outcome than ERa 1 PR 2 tumours 4 , clinical response to ERa antagonists can vary, even among tumours with similar ERa and PR status 15, 16 , and recent evidence suggests that PR may be prognostic, but not predictive 17 . Some ERa 1 PR 2 tumours that are resistant to one class of ERa antagonists gain clinical benefit from another class, suggesting that in a subset of ERa 1 PR 2 breast cancers, the lack of PR expression does not reflect a non-functional ERa complex. It has been proposed that the non-functional ERa complex theory cannot completely explain PR negativity 18 . An alternative hypothesis is that other factors contribute to the loss of PR expression, which consequently influences breast tumour responses to ERa target therapies.
PR is recruited to the ERa complex
Given the controversial and complex interplay between the ERa and PR pathways in breast cancer, we explored the possible functional crosstalk between these two transcription factors and the implications for clinical prognosis in ERa 1 disease. Ligand-activated ERa and PR protein complexes were purified to ascertain interplay between these two transcription factors. Asynchronous ERa 1 PR 1 MCF-7 and T-47D breast cancer cells were grown in stable isotope labelling by amino acids in cell culture (SILAC) growth media, which contains sufficient oestrogen to elicit maximal ERa binding to chromatin 19 . Oestrogen treatment is required to induce detectable levels of PR in MCF-7 cells, but not in T-47D cells 20 . The two cell lines were subsequently treated with vehicle or one of two progestogens: native progesterone or the synthetic progestin R5020. Cells were cross-linked following hormone treatment and endogenous PR was immunopurified followed by mass spectrometry, using a technique we recently developed called RIME (rapid immunoprecipitation mass spectrometry of endogenous proteins) 21 . Under oestrogenic conditions, progesterone treatment induced an interaction between PR and ERa in the MCF-7 and T-47D cell lines, in support of previous findings showing a physical interaction between these two nuclear receptors 22 . In addition to ERa, progesterone treatment induced interactions between PR and known ERa-associated cofactors, including NRIP1, GATA3 and TLE3 (ref. 21 ) in both cell lines (Fig. 1a) . As expected, treatment with natural ligand decreased interaction between PR and chaperone/co-chaperone proteins such as HSP90 and FKBP4/FKBP5 (Fig. 1a) . The same findings were observed when R5020 was used as a synthetic ligand (Extended Data Fig. 1) . Interestingly, when ERa was purified under the same treatment conditions, PR was the only differentially recruited protein in both cell lines (Fig. 1b) . Moreover, the interaction between ERa and known ERa-associated cofactors was not differentially affected by progesterone treatment. A list of all interacting proteins under all experimental conditions is provided in Supplementary Table 1 . The progesteroneinduced ERa-PR interaction was confirmed by standard co-immunoprecipitation experiments in both MCF-7 and T-47D cells (Fig. 1c) . We conclude that activation of PR results in a robust association between PR and the ERa complex. However, it remains unclear what effect this may have on ERa/PR DNA binding or what the primary DNA tethering mechanism may be ( Fig. 1d) .
Progesterone reprograms ERa binding events
Since PR is a transcription factor, we hypothesized that the progestogen-induced interaction between PR and ERa alters chromatin binding properties of the ERa-cofactor complex. MCF-7 and T-47D cell lines grown in complete (oestrogenic) media were stimulated with progesterone, R5020 or vehicle control for 3 or 24 h, followed by analysis of genome-wide ERa and PR and the co-activator p300 profiles by chromatin immunoprecipitation followed by sequencing (ChIP-seq). p300 deposits the H3K27Ac mark, which is indicative of functional enhancers 23 . We found comparable ERa, PR and p300 binding at 3 h and 24 h (Extended Data Fig. 1 and data not shown) and chose 3 h for the remaining experiments. All ChIP-seq experiments were subsequently repeated in triplicate following 3 h of treatment (sample clustering is provided in Extended Data Fig. 2 ). Whereas robust ERa binding (29, 149 sites in MCF-7 cells and 8,438 sites in T-47D cells) was  observed in oestrogenic conditions, limited PR binding events were  seen under these conditions (Supplementary Table 2 ). Treatment with progesterone or the synthetic progestin R5020 in oestrogen-rich media resulted in robust PR recruitment to chromatin, with 46,191 PR binding events observed in T-47D cells with both ligands and 29,554 PR binding events in MCF-7 cells. Using DiffBind to identify differential peaks 24 that occurred following treatment of cells with progesterone or R5020, a rapid and robust redistribution of ERa binding to novel genomic loci was observed (Fig. 2a, b) . In T-47D cells, 14,223 ERa binding events were reproducibly gained following 3 h of treatment with progesterone, a finding that was similar following stimulation with R5020, confirming a predictable redistribution of ERa chromatin binding following stimulation of the PR pathway. A similar rapid redirection of ERa was observed in MCF-7 cells after progesterone or R5020 treatment (Extended Data Fig. 1 ). The ERa sites reprogrammed by progesterone are likely to be functional, as indicated by the global recruitment of the co-activator p300 ( Fig. 2b and Extended Data Fig. 2 ). These ERa binding events appear to be mediated by PR, since 99% of the gained ERa binding sites in T-47D cells overlapped with a PR binding event (Fig. 2c) (the overlap in MCF-7 cells was 94%) and motif analysis of the gained ERa sites revealed the presence of progesterone responsive elements, but not oestrogen responsive elements (Fig. 2b ). This suggests that PR mediates the interaction between the ERa-PR-p300 complex and DNA. ERa ChIP-seq was repeated in MCF-7 and T-47D cells following hormone deprivation and subsequent treatment with vehicle, oestrogen alone or progesterone alone. Single hormone treatments did not induce the ERa binding events observed under dual hormone conditions (Extended Data Fig. 3 ), confirming that the ERa reprogramming is dependent on having both receptors activated simultaneously. In addition, Forkhead motifs were enriched at the gained ERa sites and 49% of the gained ERa/PR binding events were shown to overlap with FOXA1 binding (Extended Data Fig. 4 Table 3 ).
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To identify the transcriptional targets of the progestogen-induced ERa binding events, we treated oestrogen-stimulated MCF-7 and T-47D cells with progesterone, R5020 or vehicle for 3 h and performed eight replicates of RNA-seq. In total, 470 genes were differentially regulated by dual treatment with oestrogen and progesterone or R5020 compared to oestrogen alone in both T-47D and MCF7 cell lines (Extended Data Fig. 4) . Gene set enrichment analysis (GSEA) analysis revealed a pronounced enrichment of progestogen-induced ERa binding events near genes upregulated by progestogen treatment in the presence of oestrogen (Fig. 2d) . Collectively, these findings suggest that the progestogen-mediated changes in ERa binding events are functionally significant, since they co-recruit p300 and lead to new gene expression profiles ( The relative degree of ERa reprogramming and gene expression changes following progesterone treatment was higher in T-47D cells compared to MCF-7 cells (Supplementary Table 2 ), possibly owing to the differences in PR levels between these two cell lines 20 . We assessed the PR gene (PGR) in these cell lines, which revealed copy number gain of the PGR gene in T-47D cells and a heterozygous loss of the PGR gene in MCF-7 cells (Extended Data Fig. 5 ). Exogenous expression of PR (both isoforms) in the MCF-7 cell line resulted in growth inhibition (Extended Data Fig. 6 ), confirming an anti-proliferative role for PR, via modulation of ERa transcriptional activity 9 .
Progesterone blocks ERa 1 tumour growth
To explore the hypothesis that progesterone stimulation could have beneficial effects on ERa 1 tumour growth in vivo, we established MCF-7-Luciferase xenografts in NOD/SCID/IL2Rg 2/2 (NSG) mice and exposed the mice to control (that is, no hormone), slow release oestrogen pellets or slow release oestrogen plus standard high concentration progesterone pellets 26 . Ten tumours for each condition were implanted (two tumours per mouse and five mice per condition) and tumour formation was monitored using bioluminescent imaging. After 25 days, in the absence of any hormone, tumours did not grow, but stimulation with oestrogen alone resulted in tumour growth. Cotreatment with oestrogen plus progesterone resulted in a significant decrease in tumour volume, as compared to oestrogen alone, when measured by bioluminescence (Fig. 3a , b) (P 5 0.0021) or tumour volume (P 5 0.019) (Extended Data Fig. 6 ). Immunohistochemistry confirmed that PR expression was induced under both oestrogen and oestrogen plus progesterone conditions (Extended Data Fig. 7 ), but importantly, PR will only be active under dual hormone conditions. We repeated the MCF-7 xenograft experiment in ovariectomized mice, in order to eliminate any confounding issues related to endogenous mouse hormones. Assessment of tumour growth (Extended Data Fig. 7 ) confirmed the previous finding ( Fig. 3b ) that progesterone inhibited tumour formation. We performed ERa and PR ChIPseq on six randomly selected sets of matched oestrogen or oestrogen plus progesterone stimulated xenograft tumours (taken from the final time point) and identified differentially bound ERa binding events. The major variable driving clustering of ERa binding events within tumour xenografts was the treatment condition (Extended Data Fig. 7 ). As observed in the short-term cell line experiments (Fig. 2) , oestrogen-stimulated ERa binding in the xenograft tumours was substantially altered by progesterone treatment. We observed 3,603 differentially regulated ERa binding events in xenograft tumours from oestrogen plus progesterone conditions, when compared to oestrogen-only conditions (Fig. 3c ). As such, progesterone induced a global reprogramming of ERa binding events in vivo, even following long-term hormonal treatment. 
Figure 3 | Progesterone treatment inhibits ERa
1 tumour progression. a, MCF-7-Luciferase cells were implanted in NSG mice with control, oestrogen (E2) pellets or oestrogen plus progesterone (E2 1 Prog) pellets (n 5 10). b, Graphical representation of tumour formation, as assessed by bioluminescence. c, ERa ChIP-seq was conducted on randomly chosen (n 5 6) xenograft tumours from ovariectomized NSG mice treated with oestrogen alone or oestrogen plus progesterone. MA (log ratios and means average) plot representing changes in ERa binding. d, Proliferative responses (Ki67 staining) of primary breast cancer tissues cultured ex vivo with oestrogen (E2) or progestin (R5020) alone or both in combination (n 5 14 samples per treatment; except for vehicle (n 5 11) and R5020 treatments (n 5 12)). The P value was calculated using a linear mixed effect analysis. e, Representative images of Ki67 immunostaining in ex vivo cultured breast tumour tissue sections from two patients. f, MCF-7 xenografts were grown in NSG mice in the presence of oestrogen pellets. Mice were treated with vehicle, tamoxifen, progesterone or tamoxifen plus progesterone and normalized tumour volume is shown. The data were analysed using a t-test and the error bars represent 6s.e.m.
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To extend our findings into primary tumours, we employed a novel ex vivo primary tumour culture system 27, 28 to cultivate ERa 1 PR 1 primary tumours for short time periods, in order to study the effect of hormonal treatment on cell growth. Fourteen independent ERa 1 PR 1 primary tumours were used for the analysis. Each tumour was cut into small pieces and randomized onto gelatine sponges halfsubmersed in media to sustain tissue architecture and viability. Tumour explants were then cultivated under hormone-deprived conditions for 36 h, followed by a 48 h treatment with vehicle control, oestrogen, the synthetic progestin R5020 or oestrogen plus R5020. Tumours retained normal cellular and morphological features after treatment in the ex vivo context (Extended Data Fig. 8 ). Fixed tissues were stained for Ki67 to assess changes in proliferation. Most of the tumours responded to oestrogen with a coincident increase in the percentage of cells that expressed Ki67. Co-treatment with progestin significantly inhibited oestrogen-stimulated proliferation ( Fig. 3d and Extended Data Fig. 8) , showing that progesterone can antagonise oestrogen-induced growth in primary human breast tumours cultivated as explants. Example images are shown in Fig. 3e . Importantly, the addition of progestin alone did not increase growth rates ( Fig. 3d and Extended Data Fig. 8 ), in support of our hypothesis that progesterone lacks proliferative potential and importantly, is anti-proliferative in an oestrogen-driven context. ERa and PR co-localization was confirmed in the explant tumour samples using immunofluorescence, as was the reduction in Ki67 following progestogen treatment (Extended Data Fig. 8 ).
Given our findings that progestogens are anti-proliferative in an oestrogen-driven tumour context, we combined progesterone treatment with a standard of care therapy in xenograft models. MCF-7 xenografts were implanted in NSG mice and supplemented with slowrelease oestrogen pellets. Mice were subsequently treated with vehicle, progesterone alone, tamoxifen alone or progesterone plus tamoxifen and tumour growth was monitored. As previously seen ( Fig. 3b and Extended Data Fig. 6 ), progesterone antagonised oestrogen-induced tumour formation, as did tamoxifen alone, but the combination of tamoxifen plus progesterone had the greatest tumour inhibitory effect (Fig. 3f) . This experiment was repeated in a second xenograft model (T-47D cells), confirming the finding that tumour volume was inhibited by progesterone alone, but the greatest degree of tumour inhibition was observed under conditions where an ERa antagonist (tamoxifen) was coupled with a PR agonist (progesterone) (Extended Data Fig. 6 ).
PGR copy number alterations are common
Given the PGR copy number loss observed in the MCF-7 cell line (Extended Data Fig. 5 ), we explored whether this was a common phenomenon observed in breast cancer patients, by assessing genomic copy number alterations (CNA) within the METABRIC cohort of ,2,000 breast cancers 29 . This analysis revealed that 18.5% of all breast cancers possess a copy number loss in the PGR genomic locus and these are biased towards ERa 1 cases (Fig. 4a ). This level of loss of heterozygosity (LOH) has been previously observed at this genomic locus in a small cohort of patients 30 . In total, 21% of ERa 1 breast cancers contain a heterozygous or a homozygous deletion of the PGR genomic locus and these tumours had significantly (P , 0.001) lower PR messenger RNA levels (Fig. 4b) . Importantly, within the 1,484 ERa 1 cases, tumours with copy number loss of the PGR genomic region had a poorer clinical outcome (P 5 0.001) (Fig. 4c) , suggesting that inactivation of the PGR gene contributes to worse outcome within this subset of ERa tumours.
ERa mRNA levels are significantly higher in tumours with PGR copy number loss (Fig. 4d) . Copy number loss of PGR affects gene expression events, since the expression level of genes shown to be progestogen-induced under oestrogenic conditions in the cell lines was significantly lower (P , 0.001) in tumours with PGR copy number loss and, inversely, the expression level of genes repressed by progestogens in cell lines was significantly elevated (P 5 0.001) in tumours with copy number loss of the PGR gene (Fig. 4e) .
Using PAM50 breast cancer subtype stratification, 33% of luminal B tumours (typically poor prognosis and PR low/negative) possessed copy number loss of the PGR genomic region (Fig. 4f) , explaining the lower PR protein levels in one third of this breast cancer subtype. In addition, even within the luminal A tumours only (which tend to have a better outcome), 19% have a copy number loss of PGR and this subset of luminal A tumours have a poorer clinical outcome (Extended Data Fig. 9 ). Tumours were then stratified based on the ten recently described genomic integrative clusters 29 , revealing three ERa 1 subtypes (integrative clusters 1, 2 and 6) with at least 35% PGR copy number loss (Fig. 4g ). All three of these integrative clusters have intermediate or poor clinical outcome (Fig. 4g) . Data showing genomic copy number changes on the chromosome 11 arm that encompasses the PGR gene are shown in Extended Data Fig. 9 . This level of PGR copy number loss was even higher in an independent cohort of breast cancer patients: 29% of luminal (ERa 1 ) breast cancers from Fig. 10 ). Within luminal B tumours only, 39% of TCGA breast cancer cases had a PGR copy number loss.
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Our data show that PR and ERa are functionally linked in breast cancer cells with a greater complexity than previously recognized. Good prognosis luminal A ERa 1 PR 1 breast tumours, when exposed to both oestrogens and progestogens, have an ERa chromatin binding profile that is dictated by PR binding events. The functional significance of this steroid receptor crosstalk is regulation of a gene expression program associated with low tumorigenicity; hence, better disease outcome. Genomic alterations in the PGR genomic locus seem to be a relatively common mechanism for reduction of PR expression, which may consequently lead to altered ERa chromatin binding and target gene expression patterns that increase breast tumorigenicity and confers a poor clinical outcome. This ERa-PR crosstalk may be directly influenced by many variables, including the relative receptor levels and the hormonal milieu. The presence or absence of oestrogen may significantly alter the outcome of PR-ERa interactions, such that the antiproliferative effects of PR activation may be limited to oestrogenic conditions. Our findings show that PR is not simply a marker of a functional ERa complex 18 . Rather, we propose that PR is a critical determinant of ERa function owing to crosstalk between PR and ERa. In this scenario, under oestrogenic conditions, an activated PR functions as a proliferative brake in ERa 1 breast tumours by re-directing ERa chromatin binding and altering the expression of target genes that induce a switch from a proliferative to a more differentiated state 6 .
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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METHODS
Cell lines and SILAC labelling of cell lines. MCF-7 and T-47D human cell lines were obtained directly from ATCC and grown in DMEM, supplemented with 10% FBS. All cell lines were regularly genotyped using STR profiling using the Promega GenePrint 10 system. Cell lines were regularly tested for mycoplasma infection. Rapid IP-mass spectrometry of endogenous protein (RIME). Rapid immunoprecipitation-mass spectrometry experiments were performed as previously described 21 . MCF-7 and T-47D cells were grown in R/K-deficient SILAC DMEM (PAA; E15-086), 10% dialysed serum (Sigma-Aldrich; F0392), and supplemented with 800 mM L-lysine 13 C 6 15 N 2 hydrochloride and 482 mM L-arginine 13 C 6 15 N 4 hydrochloride (Sigma-Aldrich) for 'heavy'-labelled media or 800 mM L-lysine 12 C 6 14 N 2 hydrochloride and 482 mM L-arginine 12 C 6 14 N 4 hydrochloride for 'light'-labelled media. Antibodies used were against ERa (Santa Cruz -sc-543, lot-A2213) and PR (Santa Cruz-sc-7208, lot H2312). 20 mg of each antibody was used for each RIME experiment.
Each RIME experiment was performed by mixing 20 million cells from each label after respective drug treatments. Cells were treated with either progesterone (100 nM), R5020 (10 nM) or vehicle (ethanol). Two replicates of each experiment was performed and the results were validated by switching the SILAC labels. The RIME method, mass spectrometry and data analysis were performed as previously described 21 . Western blot and co-immunoprecipitation. Immunoprecipitation experiments for ERa and PR were performed using Santa Cruz antibodies. Antibodies used were against ERa (sc-543) and PR (sc-7208). Western blots for ERa and PR were performed using Novocastra antibodies (ERa: NCL-L-ER6F11 and PR: NCL-L-PGR-AB). ChIP-seq. ChIP-seq experiments were performed as described 32 . Antibodies used were against ERa (Santa Cruz -sc-543, lot-A2213), PR (Santa Cruz-sc-7208, lot H2312) and p300 (Santa Cruz sc-585, lot -E2412). 10 mg of antibody was used for each experiment. Cells were treated with either progesterone (100 nM), R5020 (10 nM) or vehicle (ethanol) and experiment was performed in triplicates.
For xenograft experiments, ERa ChIP-seq experiments were performed from six sets of randomly chosen tumours under oestrogen only or progesterone and oestrogen treatment condition. Also included were two tumours from vehicle (control) conditions. Animals were randomly assigned to treatment groups using a random number generator at the beginning of the study. ChIP-seq data analysis. Statistical tests and cut-offs were selected based on published recommendations 24 . RNA-seq. RNA-sequencing experiments were performed in MCF-7 and T-47D cells. Cells were treated with progesterone (100 nM) or R5020 (10 nM) for 3 h and RNA extracted. Experiment was performed in eight replicates for each cell line. RNA-seq analysis. Single-end 40-bp reads generated on the Illumina HiSeq sequencer were aligned to the human genome version GRCh37.64 using TopHat v2.0. 4 (ref. 33) . Read counts were then obtained using HTSeq-count v0.5.3p9 (http://www-huber.embl.de/users/anders/HTSeq/doc/overview.html). Read counts were then normalized and tested for differential gene expression using the DESeq 34 workflow. Multiple testing correction was applied using the Benjamini-Hochberg method. Genes were selected as differentially expressed such that false discovery rate (FDR) ,0.01. GSEA analysis. Integration of the RNA-seq data and the ChIP-seq DBA results were carried out using gene set enrichment analysis (GSEA) 35 as follows. All genes assessed by RNA-seq were ranked and weighted by their mean log 2 fold change on progesterone treatments. Lists of genes that overlapped with regions showing significant differential binding on progesterone treatment were derived. These data were then analysed using the GSEA v2.0.13 GSEA Preranked tool. Gene signature analysis. We derive a prognostic gene signature of consisting of progesterone regulated genes. We included genes that were determined by RNAseq (see above) as differentially upregulated in T47-D cells when subjected to progesterone/progestin, as well as having a differentially bound ER binding site with increased binding affinity (determined using DiffBind) within 10 kb of the transcription start site. 38 genes met these criteria (see Extended Data Fig. 5 ). This signature was validated using the METABRIC expression data set (15) , showing that patients in the highest 10% of expression of genes in the signature exhibit significantly better breast cancer specific survival than patients in the lowest 10% of expression (P 5 7.36 3 10 As it has been shown that many gene signatures have significant power to predict outcome in breast cancer 36 , we subjected the signature to additional statistical tests using the Bioconductor package SigCheck 37 . We used SigCheck to generate a null distribution of 1,000 signatures consisting of 38 genes selected at random, and computed their survival P values using the survival data for the 392 patients with high or low expression over the progesterone induced genes. The progesterone induced signature performed in the 99th percentile, with 1.2% of random signatures demonstrating an equal or lessor P value (empirical P value 5 0.012; Extended Data Fig. 5 Tissue collection and processing. Excised tissue samples were delivered to the laboratory on ice within one hour following surgery and washed in culture medium comprised of phenol red-free RPMI (SAFC Biosciences, Kansas, USA), 200 mM glutamine (SAFC Biosciences), 13 antibiotic-antimycotic (SigmaAldrich), 10 mg/ml insulin (Sigma-Aldrich), and 10 mg/ml hydrocortisone (Sigma-Aldrich). Breast tumour tissues were cultured ex vivo as previously described 28 . In brief, tumour pieces (explants) were pre-incubated on gelatine sponges (3-4 per sponge) for 36 h in culture media containing 10% FCS, followed by treatment with hormones as indicated in culture media containing 10% steroid depleted FCS. The conditions used were: vehicle, oestradiol (10 nM), R5020 (10 nM) and the combination of oestradiol and R5020 (both at 10 nM) with hormone treatment conducted for 48 h. Representative pieces of tissue were fixed in 4% formalin in phosphate-buffered saline (PBS) at 4 uC overnight and subsequently processed into paraffin blocks. Sections (2 mm) were stained with haematoxylin and eosin and examined by a pathologist to confirm and quantify the presence/proportion of tumour cells. Immunohistochemistry. Primary antibodies to detect ERa (ID5 1:300; DAKO M7047, Glostrup, Denmark), PR (1:1,000, Leica NCL-PGR-AB, Wetzlar, Germany) or Ki67 (MIB1 1:400; DAKO M7240 Glostrup, Denmark) were used in conjunction with a 1:400 dilution of a biotinylated anti-mouse secondary antibody for 30 min (DAKO E0433, Glostrup, Denmark) followed by incubation with horseradish peroxidase-conjugated streptavidin (DAKO P0397, Glostrup, Denmark). Visualization of immunostaining was performed using 3,3-diaminobenzidine (Sigma D9015), as previously described 38 . Image capture and quantification of Ki67 immunostaining. Slides were scanned at 403 magnification (NanoZoomer Microscopy System, Hamamatsu, Japan) and the digitized images edited to exclude non-glandular structures. A minimum of 10 high-resolution images from Nanozoomer files of all segments were recorded. Brown pixels (Ki67) and blue pixels (haematoxylin) were extracted from each image using Adobe Photoshop and the Colour Range tool and a fuzziness factor of 20. Extracted pixels were converted to greyscale format and a consistent threshold applied. Absolute numbers and proportion of Ki67-positive cells were determined using ImageJ software and the Analyse Particles tool with a circularity index of 0.2-1. An average of 14,000 cells were quantified per sample. Accuracy of automatic quantification was determined using an independent set of images that were assessed by an offsite independent observer who manually counted Ki67-positive and Ki67-negative cells in high-resolution images systematically sampled from an individual patient sample (containing .6,500 cells). Identical images were analysed by automatic quantification with consistency between manual and automatic counting of .95%. A linear mixedeffects model of percentage Ki67-positive cells versus type of treatment, adjusting for clustering on patient, was used to assess statistical significance. Immunofluorescence. 5-mm sections were cut and adhered to Superfost UltraPlus slides (Menzel-Glasser Braunscweig, Germany) and baked on a warm block at 60 uC for 1 h. Sections were dewaxed in 3 3 5 min immersions of xylene followed by 3 3 5 min immersions in 100% ethanol. Sections were rehydrated in 2 3 5 min immersions in 70% ethanol followed by 2 3 5 min immersions in distilled H 2 O. Next, antigen retrieval was performed in 600 ml of 1 mM Na-EDTA (pH 8.0) by heating in an 800 W microwave until boiling (approximately 5 min), allowing slides to stand for 5 min before microwaving at 50% power for an additional 5 min. Slides were allowed to cool in antigen retrieval buffer for 60 min before transferring to PBS for 5 min. Sections were encircled with a wax pen and primary antibody diluted in PBS with 10% normal goat serum was applied overnight at 4 uC (rat anti-ERa 1:100 (Abcam ab46186); mouse anti-PR 1:500 (Dako NCL-PGR-AB); rabbit anti-Ki67 1:100 (Abcam ab16667). Sections were washed twice for 5 min in PBS, followed by incubation with secondary antibody diluted (all at 1:400) in PBS with 10% normal goat serum for 30 min at room temperature (goat anti-rat Alexa488 (A11006); goat anti-mouse Alexa569 (A11031); goat RESEARCH ARTICLE anti-rabbit Alexa647, (A21246.), Life Technologies). Sections were washed twice for 5 min in PBS, followed by incubation with 1 nM DAPI diluted in PBS for 2 min at room temperature. Sections were mounted under DAKO fluorescent mounting media (S3023) and each fluorescent channel captured separately using a Zeiss LSM700 confocal microscope. PGR copy number analysis. Matched DNA and RNA were extracted for 1,980 tumours. The copy number analysis was performed using the Affymetrix SNP 6.0 platform. The arrays were first pre-processed and normalized using CRMAv2 39 method from the aroma.affymetrix R package. For each array, allelic-crosstalk calibration, probe sequence effects normalization, probe-level summarization and PCR fragment length normalization were performed. Then the intensities were normalized against a pool of 473 normals for those samples that had no matched normal or against their matched normal when available. The log-ratios were segmented using the CBS algorithm 40 in the DNAcopy Bioconductor package. Then, callings into five groups (homozygous deletion, heterozygous deletion, neutral copy number, gain and amplification), were made using thresholds based on the variability of each sample and their proportion of normal contamination. Then, samples were classified as PGR loss if they showed any type of loss in any part of the gene.
RNA analysis was performed using Illumina HT-12 v3 platform and analysed using beadarray package 41 . BASH 42 algorithm was employed to correct for spatial artefacts. Bead-level data were summarized and a selection of suitable probes based on their quality was done using the re-annotation of the Illumina HT12v3 platform 43 . The samples were classified into the five breast cancer subtypes using PAM50 44 and the 10 integrative clusters 29 . Two-sided t-tests were performed between expression values and loss of PGR to determine significance. Kaplan-Meier estimates and log-rank tests were obtained using the survival R package (http://CRAN.R-project.org/package5survival). Comparison of the expression of the stringent progesterone/R5020 induced or repressed genes in samples with PGR lost and not lost was performed averaging the expression of all the genes and running a two-sided t-test. Xenograft experiments. Mice were maintained, and regulated procedures performed, according to UK Home Office project license guidelines. Sample size was calculated using a combination of the NC3Rs recommended Resource Equation method, and also prior knowledge of the experimental variability of breast cancer cell line xenografts in NSG animals. All in vivo experiments were performed using age matched female NOD/SCID/IL2Rg 2/2 (NSG) mice and all experiments were blinded. Animals were selected using the following criteria: sex (female) and age matched (where possible littermates were used) to reduce variability; only animals in excellent health were used (verified pathogen free and in excellent physical health); all animals were certified as NSG strain. Animals were randomly assigned to treatment groups using a random number generator at the beginning of the study. Briefly, mice were injected subcutaneously into the No. 4 inguinal mammary fat pad with a suspension of 10 5 MCF7-Luc2/YFP cells in 50% growth factor reduced Matrigel (BD Biosciences). Where appropriate, 90 day slowreleasing 17b-oestradiol (0.72 mg per pellet) and/or progesterone (10 mg per pellet) hormone pellets (Innovative Research of America) were implanted subcutaneously in recipient mice. Tumour growth was monitored using regular bioluminescent imaging (IVIS) and caliper measurement. Data were analysed using the GraphPad Prism statistical software package. Standard deviations within groups were similar and substantially less than the variation between the treatment groups. Sample size was determined by a pilot experiment with a smaller number of mice. Mice used for all experiments were age and litter matched (3 months) to reduce variability. 15 mice were injected with tumours and then 5 mice were selected at random for each treatment arm. Treatments were blinded using coded cages. Mice were regularly assessed for health and endpoint was determined on regulatory guidelines for tumour size.
For tamoxifen experiments, age-matched female NSG mice were injected as above with either 10 5 MCF7-Luc2/YFP cells or 10 7 T-47D-Luc2/mStrawberry cells in 50% growth factor reduced Matrigel (BD Biosciences). Concomitantly, a 90 day slow-release 17b-oestradiol (0.72 mg per pellet) (Innovative Research of America) was implanted subcutaneously. One week later either 90 day slowrelease progesterone (10 mg per pellet) hormone or placebo pellets (Innovative Research of America) were implanted subcutaneously, and tamoxifen/vehicle administration was commenced. 100 ml tamoxifen (5 mg/mL) or vehicle (sterile filtered corn oil) were administered i.p. to a schedule of 3 days dosing/ 1 day rest for a total duration of 4 weeks (MCF7) or 8 weeks (T-47D). Tumour sizes were monitored as above. Each treatment arm consisted of 10 tumours.
For ovariectomy experiments, age matched female NSG mice were injected as before with 10 5 MCF7-Luc2/YFP cells in 50% growth factor reduced Matrigel (BD Biosciences), and 90 day slow-release 17b-oestradiol (0.72 mg per pellet) and/or progesterone (10 mg per pellet) and/or placebo hormone pellets (Innovative Research of America) were implanted subcutaneously in recipient mice. Concomitantly, ovariectomy was performed. Tumour sizes were monitored as above for 7 weeks. Each treatment arm consisted of 10 tumours.
Extended Data Figure 1 | Protein purification of ERa and PR interacting proteins, using RIME, following treatment with a synthetic progestin. T-47D and MCF-7 breast cancer cells were grown in SILAC-isotope containing media and treated with either vehicle control or R5020, a synthetic progestin for 3 h. PR (a) or ERa (b) RIME was conducted and the proteins that were quantitatively enriched in both cell lines are shown. Only proteins that were enriched with a FDR , 1% were included. c, Peptide coverage of the PR protein following ERa RIME in T-47D cells. The identified peptides are highlighted and one of the peptides covers the 'Bus' region representing the PR-B isoform. ChIP-seq from xenograft tumours in ovariectomized mice. a, Histological analysis of MCF-7 xenograft tumours in untreated, oestrogen or oestrogen plus progesterone conditions. Tumours were taken from 25 day treated conditions. The human xenograft cells expressed GFP, permitting discrimination between human tumour cells and mouse host cells. MCF-7 xenograft experiment in ovariectomized mice. b, In order to map ERa binding events by ChIP-seq in MCF-7 xenograft tumours, we repeated the experiment in ovariectomized mice to eliminate any issues related to the endogenous mouse progesterone. Ten tumours for each condition (two in each of five mice per condition) were included. Growth of xenograft tumours under different hormonal conditions, Control, oestrogen alone (E2) and oestrogen plus progesterone (E2 1 Prog). The data were analysed using a t-test and the error bars represent 6s.e.m. c, ChIP-seq for ERa and PR were conducted in six matched tumours from each hormonal condition. Also included were two tumours from no hormone conditions. Correlation heat map of all samples. 
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Extended Data Figure 10 | Validation of genomic copy number loss in the PGR gene in an independent data set. a, TCGA ERa 1 breast cancers were assessed for copy number changes in PGR. The number of tumours in each category, based on copy number changes. Only ERa 1 breast cancers were included. b, Correlation between PR mRNA levels and copy number status in all luminal breast cancers within the TCGA cohort. The heterozygous and homozygous deletions are combined. c, Frequency of copy number alterations across entire genome in TCGA breast cancer cohort, stratified based on subtype using PAM50 signature. Chromosome 11, which encompasses PGR gene is highlighted and the frequency of copy number loss of the PGR genomic region is provided. d, Copy number changes on chromosome 11 within the METABRIC cohort, based on subtype stratification (PAM50 signature).
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